Skip to main content
. 2022 Nov 14;3:1007593. doi: 10.3389/falgy.2022.1007593

Table 2.

Monoclonal antibodies’ efficacy in different comorbidities.

Allergic Rhinitis Nasal polyps Urticaria Atopic dermatitis Vasculitis (EGPA)
Omalizumab Yes Yes Yes
Mepolizumab Yes Yes
Reslizumab
Benralizumab
Dupilumab Yes Yes
Tezepelumab

EGPA, eosinophilic granulomatosis with polyangiitis.